BGNE:NSD-BeiGene Ltd (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 197.28

Change

-0.23 (-0.12)%

Market Cap

USD 21.94B

Volume

0.19M

Analyst Target

USD 237.90
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. Its commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and PARTRUVIX, a selective small molecule inhibitor of PARP1 and PARP2 enzymes that is being evaluated as a monotherapy and in combinations for the treatment of various solid tumors. The company's clinical stage products comprise BGB-11417, a small molecule Bcl-2 inhibitor; BGB-16673, a BTK-targeting chimeric degradation activation compound active against wild-type and mutant BTK; BGB-10188; BGB-21447, a Bcl-2 inhibitor; Ociperlimab (BGB-A1217), a TIGIT inhibitor; Zanidatamab, a bispecific HER2-targeted antibody; Surzebiclimab (BGB-A425), a TIM-3 inhibitor; BGB-A445, an OX40 agonist antibody; BGB-15025, a small molecule inhibitor of HPK1; BGB-24714, a SMAC mimetic; BGB-26808, a HPK-1 inhibitor; Lifirafenib and BGB-3245 that are inhibitors of RAF; BGB-30813; BGB-A3055, an anti-CCR8 antibody; and BGB-43395, a CDK-4 inhibitor. It also has various preclinical programs. The company has license agreements with Ensem Therapeutics, Inc.; Shandong Luye Pharmaceutical Co., Ltd.; Shoreline Biosciences, Inc.; Nanjing Leads Biolabs, Inc.; EUSA Pharma; Assembly Biosciences, Inc.; Bio-Thera Solutions, Ltd.; Amgen Inc.; and Beijing Novartis Pharma Co., Ltd. BeiGene, Ltd. was incorporated in 2010 and is based in Camana Bay, the Cayman Islands.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-18 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
REGN Regeneron Pharmaceuticals Inc

-7.94 (-0.69%)

USD 127.14B
VRTX Vertex Pharmaceuticals Inc

-7.10 (-1.48%)

USD 125.27B
ALNY Alnylam Pharmaceuticals Inc

-1.31 (-0.48%)

USD 35.24B
ARGX argenx NV ADR

+6.84 (+1.31%)

USD 32.19B
MRNA Moderna Inc

-2.13 (-2.96%)

USD 26.25B
SMMT Summit Therapeutics PLC

-1.66 (-6.33%)

USD 23.47B
RPRX Royalty Pharma Plc

-0.03 (-0.11%)

USD 16.45B
BMRN Biomarin Pharmaceutical Inc

+0.59 (+0.84%)

USD 16.16B
UTHR United Therapeutics Corporatio..

-2.43 (-0.70%)

USD 15.09B
PCVX Vaxcyte Inc

-0.21 (-0.18%)

USD 14.27B

ETFs Containing BGNE

XSNR:LSE Xtrackers - Stoxx Europe .. 8.01 % 0.00 %

-112.00 (-1.02%)

USD 0.03B
DXSL:XETRA Xtrackers - Stoxx Europe .. 8.01 % 0.00 %

-0.72 (-1.02%)

USD 0.02B
MSGR 6.80 % 0.00 %

N/A

N/A
L6EW:LSE Ossiam Stoxx Europe 600 E.. 6.12 % 0.00 %

-70.00 (-1.02%)

USD 0.11B
S6EW:PA Ossiam Stoxx Europe 600 E.. 6.12 % 0.00 %

-0.44 (-1.02%)

USD 0.11B
OSX6:XETRA Ossiam Stoxx Europe 600 E.. 6.12 % 0.00 %

-0.42 (-1.02%)

USD 0.16B
S6EW:SW Ossiam STOXX® Europe 600.. 6.12 % 0.00 %

N/A

USD 0.11B
BBH VanEck Biotech ETF 4.41 % 0.35 %

-0.21 (-1.02%)

USD 0.46B
FBT:LSE First Trust Global Funds .. 4.16 % 0.00 %

-18.00 (-1.02%)

USD 7.71M
FBTU:LSE First Trust Global Funds .. 4.16 % 0.00 %

-0.17 (-1.02%)

USD 7.71M
XS3R:LSE Xtrackers MSCI Europe Con.. 2.76 % 0.00 %

-143.00 (-1.02%)

USD 0.06B
DXSK:XETRA Xtrackers - Stoxx Europe .. 2.76 % 0.00 %

-1.08 (-1.02%)

USD 0.07B
ELOVD:SW UBS(Lux)Fund Solutions .. 1.98 % 0.00 %

-1.14 (-1.02%)

N/A
EDGE:CA Evolve Innovation Index F.. 1.59 % 0.60 %

+0.07 (+-1.02%)

CAD 0.04B
EDGE-U:CA Evolve Innovation Index F.. 1.59 % 0.00 %

N/A

N/A
ELOW:SW SPDR® EURO STOXX Low Vol.. 1.17 % 0.00 %

-0.15 (-1.02%)

N/A
PHR:CA 0.00 % 0.78 %

N/A

N/A
KURE KraneShares MSCI All Chin.. 0.00 % 0.79 %

-0.09 (-1.02%)

USD 0.04B
KMED 0.00 % 0.79 %

N/A

N/A
GDNA 0.00 % 0.00 %

N/A

N/A
XRE:CA iShares S&P/TSX Capped RE.. 0.00 % 0.61 %

+0.02 (+-1.02%)

CAD 1.27B
FLHK Franklin FTSE Hong Kong E.. 0.00 % 0.09 %

+0.03 (+-1.02%)

USD 0.01B
S6EW:LSE Ossiam Stoxx Europe 600 E.. 0.00 % 0.00 %

-0.48 (-1.02%)

N/A
LOWE:LSE 0.00 % 0.00 %

N/A

N/A
XMLA:LSE Xtrackers MSCI EM Latin A.. 0.00 % 0.00 %

-4.00 (-1.02%)

N/A
XMLD:LSE Xtrackers MSCI EM Latin A.. 0.00 % 0.00 %

+0.02 (+-1.02%)

N/A
XDGM:LSE 0.00 % 0.00 %

N/A

N/A
EMMV:PA 0.00 % 0.00 %

N/A

N/A
DXSK:F Xtrackers - Stoxx Europe .. 0.00 % 0.00 %

-0.96 (-1.02%)

N/A
EUN0:F iShares Edge MSCI Europe .. 0.00 % 0.00 %

-0.04 (-1.02%)

N/A
OSX6:F Ossiam Lux - Ossiam Stoxx.. 0.00 % 0.00 %

N/A

N/A
EUN0:XETRA iShares Edge MSCI Europe .. 0.00 % 0.00 %

-0.29 (-1.02%)

USD 0.79B
OSX9:XETRA 0.00 % 0.00 %

N/A

N/A
UIMY:XETRA 0.00 % 0.00 %

N/A

N/A
TGRE:CA TD Active Global Real Est.. 0.00 % 0.00 %

-0.01 (-1.02%)

CAD 0.07B
TPIF Timothy Plan Internationa.. 0.00 % 0.00 %

-0.17 (-1.02%)

USD 0.12B
BIOT 0.00 % 0.00 %

N/A

N/A
LCDE:XETRA BNP Paribas Easy - Low Ca.. 0.00 % 0.00 %

-0.07 (-1.02%)

USD 0.02B
MVEU:SW iShares Edge MSCI Europe .. 0.00 % 0.00 %

-0.60 (-1.02%)

USD 0.77B

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 9.38% 68% D+ 68% D+
Dividend Return N/A N/A N/A N/A N/A
Total Return 9.38% 68% D+ 66% D+
Trailing 12 Months  
Capital Gain 2.30% 59% D- 47% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 2.30% 59% D- 45% F
Trailing 5 Years  
Capital Gain 45.57% 78% C+ 72% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 45.57% 78% C+ 69% C-
Average Annual (5 Year Horizon)  
Capital Gain 12.49% 68% D+ 70% C-
Dividend Return 12.49% 68% D+ 68% D+
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 55.71% 58% F 32% F
Risk Adjusted Return 22.41% 79% B- 57% F
Market Capitalization 21.94B 99% N/A 96% N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.